GSK Bundles Legacy Drugs Into Separate Portfolio In Housekeeping Move
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline is bundling around 50 legacy drugs comprising some £3 billion ($4.6 billion) in annual sales into a standalone global portfolio, in a “housekeeping” move that Britain’s biggest medicines maker says is needed to better prepare the group for its coming wave of new product launches.